Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Norwegian EPJ (electronic patient journal) nearing completion:

This article was originally published in Clinica

Executive Summary

Standardisation of the Norwegian electronic patient journal (EPJ) is to be completed by the end of June, says the competence centre for IT in the health service (KITH). Its aim is to provide a unified platform for journals in hospitals, primary care and other healthcare institutions in accordance with the law. The KITH is intending that all available patient journals will be prepared for the conversion to an electronic system in 2002. It also envisages that within a period of 3-5 years, all of Norway's hospitals will be employing an EPJ system. At present, 90% of primary care doctors employ an EPJ, but the hospital system is far behind. Work on the journal has been ongoing since 1998 and has been part of the department of health's plans to develop IT in the health system. It has the backing of the Norwegian doctors' association.

You may also be interested in...

Oxford/AZ’s COVID-19 Vaccine Cuts Virus Spread By 60%

Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.

GemVax Aims For Alzheimer’s 'Game Changer' As Phase III Approaches

After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.

QUOTED. 25 November 2020. Ricki Chase.

The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts